Увійти

Готові списки джерел за темами / Cancer immunotherapies / Статті в журналах

Статті в журналах з теми "Cancer immunotherapies"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Cancer immunotherapies.

Автор: Grafiati

Опубліковано: 10 грудня 2022

Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Cancer immunotherapies".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

Bergman, Philip J. "Cancer Immunotherapies." Veterinary Clinics of North America: Small Animal Practice 49, no. 5 (September 2019): 881–902. http://dx.doi.org/10.1016/j.cvsm.2019.04.010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

DAVIS, Ian D., and Jonathan S. CEBON. "Developing cancer immunotherapies." Asia-Pacific Journal of Clinical Oncology 7 (March 24, 2011): 9–13. http://dx.doi.org/10.1111/j.1743-7563.2011.01382.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Ott, Patrick A. "Intralesional Cancer Immunotherapies." Hematology/Oncology Clinics of North America 33, no. 2 (April 2019): 249–60. http://dx.doi.org/10.1016/j.hoc.2018.12.009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

&NA;. "Immunotherapies for cancer reviewed." Inpharma Weekly &NA;, no. 1432-1433 (April 2004): 2. http://dx.doi.org/10.2165/00128413-200414320-00001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Gubens, Matthew A. "Immunotherapies for Lung Cancer." Journal of the National Comprehensive Cancer Network 15, no. 5S (May 2017): 692–95. http://dx.doi.org/10.6004/jnccn.2017.0075.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Fakhrejahani, Farhad, Yusuke Tomita, Agnes Maj-Hes, Jane B. Trepel, Maria De Santis, and Andrea B. Apolo. "Immunotherapies for bladder cancer." Current Opinion in Urology 25, no. 6 (November 2015): 586–96. http://dx.doi.org/10.1097/mou.0000000000000213.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Berraondo, Pedro, Sara Labiano, Luna Minute, Iñaki Etxeberria, Marcos Vasquez, Alvaro Sanchez-Arraez, Alvaro Teijeira, and Ignacio Melero. "Cellular immunotherapies for cancer." OncoImmunology 6, no. 5 (May 2, 2017): e1306619. http://dx.doi.org/10.1080/2162402x.2017.1306619.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Mulé, James J., and Jeffrey S. Weber. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1153. http://dx.doi.org/10.1038/nm1104-1153a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Pardoll, Drew, and James Allison. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1153–54. http://dx.doi.org/10.1038/nm1104-1153b.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Skipper, Jonathan, Eric W. Hoffman, Jill O'Donnell-Tormey, and Lloyd J. Old. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1154–55. http://dx.doi.org/10.1038/nm1104-1154.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Pardoll, Drew, and James Allison. "Translation of cancer immunotherapies." Nature Medicine 10, no. 11 (November 2004): 1155. http://dx.doi.org/10.1038/nm1104-1155a.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

García-Martínez, Elena, and J. Alejandro Pérez-Fidalgo. "Immunotherapies in ovarian cancer." European Journal of Cancer Supplements 15 (August 2020): 87–95. http://dx.doi.org/10.1016/j.ejcsup.2020.02.002.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Roy, Ruchi, Sunil Kumar Singh, and Sweta Misra. "Advancements in Cancer Immunotherapies." Vaccines 11, no. 1 (December 27, 2022): 59. http://dx.doi.org/10.3390/vaccines11010059.

Повний текст джерела

Анотація:

Recent work has suggested involvement of the immune system in biological therapies specifically targeting tumor microenvironment. Substantial advancement in the treatment of malignant tumors utilizing immune cells, most importantly T cells that play a key role in cell-mediated immunity, have led to success in clinical trials. Therefore, this article focuses on the therapeutic approaches and developmental strategies to treat cancer. This review emphasizes the immunomodulatory response, the involvement of key tumor-infiltrating cells, the mechanistic aspects, and prognostic biomarkers. We also cover recent advancements in therapeutic strategies.

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Saly, Danielle L., and Mark A. Perazella. "The adverse kidney effects of cancer immunotherapies." Journal of Onco-Nephrology 2, no. 2-3 (June 2018): 56–68. http://dx.doi.org/10.1177/2399369318808806.

Повний текст джерела

Анотація:

Cancer therapies are a common cause of acute and chronic kidney disease, which are increasingly being seen by nephrologists in clinical practice. Conventional chemotherapeutic drugs and novel targeted agents are effective cancer therapies but their use is complicated by nephrotoxicity. Cancer immunotherapies exploit various properties of immune cells to enhance immune-mediated tumor killing. Interferon and high-dose interleukin-2 are older immunotherapies first employed clinically in the 1980s and 1990s to treat a number of different cancers. While effective, these two therapies have well-known systemic toxicities, which include acute kidney disease. The emergence of the new cancer immunotherapies over the past decade brings more effective treatment options. The immune checkpoint inhibitors and chimeric antigen receptor T cells are exciting additions to the cancer treatment armamentarium. These agents effectively treat a several and a growing list of cancers that have otherwise failed other therapies. However, as with the conventional and targeted cancer agents, drug-induced acute and chronic kidney disease is an untoward effect of this group of drugs. We will undertake a case-based review: the newer immunotherapies followed by the older therapies, interferon and interleukin-2.

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Yi, Qing. "Novel Immunotherapies." Cancer Journal 15, no. 6 (November 2009): 502–10. http://dx.doi.org/10.1097/ppo.0b013e3181c51f0d.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Slaney, Clare Y., and Michael H. Kershaw. "Challenges and Opportunities for Effective Cancer Immunotherapies." Cancers 12, no. 11 (October 28, 2020): 3164. http://dx.doi.org/10.3390/cancers12113164.

Повний текст джерела

Анотація:

Using immunotherapy to treat cancers can be traced back to the 1890s, where a New York physician William Coley used heat-killed bacteria to treat cancer patients, which became known as “Coley’s toxin” [...]

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Platten, Michael, and David Reardon. "Concepts for Immunotherapies in Gliomas." Seminars in Neurology 38, no. 01 (February 2018): 062–72. http://dx.doi.org/10.1055/s-0037-1620274.

Повний текст джерела

Анотація:

Strategies to empower the immune system to successfully attack cancers, including vaccination approaches, adaptive T cell therapies, and immune checkpoint modulators, have recently achieved remarkable success across a spectrum of cancer indications. Nonetheless, with rare exception, only a minority of patients with a given type of cancer respond to an immunotherapeutic when administered as single-agent therapy. Although under extensive laboratory and clinical investigation, the role of these approaches for glioma patients remains to be determined. While the central nervous system (CNS) is no longer regarded as an immunoprivileged sanctuary, nuances regarding immune responses in the CNS may impact on the activity of immunotherapy treatments of brain tumor patients. Furthermore, many common CNS tumors such as World Health Organization grade III and IV (high grade) gliomas utilize myriad, nonoverlapping strategies to dampen or extinguish antitumor immune responses. For these reasons, critical research efforts are focused on identifying biomarkers that predict patients with a heightened likelihood of therapeutic benefit as well as evaluating rationally designed combinatorial immunotherapy approaches with potentially complementary mechanisms of immune-activation for brain cancer patients.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Swatler, Julian, and Ewa Kozłowska. "Immune checkpoint‑targeted cancer immunotherapies." Postępy Higieny i Medycyny Doświadczalnej 70 (January 26, 2016): 25–42. http://dx.doi.org/10.5604/17322693.1192926.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Negrini, Simone, Raffaele De Palma, and Gilberto Filaci. "Anti-Cancer Immunotherapies Targeting Telomerase." Cancers 12, no. 8 (August 12, 2020): 2260. http://dx.doi.org/10.3390/cancers12082260.

Повний текст джерела

Анотація:

Telomerase is a reverse transcriptase that maintains telomeres length, compensating for the attrition of chromosomal ends that occurs during each replication cycle. Telomerase is expressed in germ cells and stem cells, whereas it is virtually undetectable in adult somatic cells. On the other hand, telomerase is broadly expressed in the majority of human tumors playing a crucial role in the replicative behavior and immortality of cancer cells. Several studies have demonstrated that telomerase-derived peptides are able to bind to HLA (human leukocyte antigen) class I and class II molecules and effectively activate both CD8+ and CD4+ T cells subsets. Due to its broad and selective expression in cancer cells and its significant immunogenicity, telomerase is considered an ideal universal tumor-associated antigen, and consequently, a very attractive target for anti-cancer immunotherapy. To date, different telomerase targeting immunotherapies have been studied in pre-clinical and clinical settings, these approaches include peptide vaccination and cell-based vaccination. The objective of this review paper is to discuss the role of human telomerase in cancer immunotherapy analyzing recent developments and future perspectives in this field.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Basler, Michael, and Marcus Groettrup. "Advances in Prostate Cancer Immunotherapies." Drugs & Aging 24, no. 3 (2007): 197–221. http://dx.doi.org/10.2165/00002512-200724030-00003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Capsomidis, Anna, and John Anderson. "Developing immunotherapies for childhood cancer." Archives of disease in childhood - Education & practice edition 102, no. 3 (September 29, 2016): 162–65. http://dx.doi.org/10.1136/archdischild-2016-311284.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Kim, Joseph W., Yusuke Tomita, Jane Trepel, and Andrea B. Apolo. "Emerging immunotherapies for bladder cancer." Current Opinion in Oncology 27, no. 3 (May 2015): 191–200. http://dx.doi.org/10.1097/cco.0000000000000177.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Weller, M. "Neurologic complications of cancer immunotherapies." Journal of the Neurological Sciences 405 (October 2019): 46–47. http://dx.doi.org/10.1016/j.jns.2019.10.130.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Willis, M. D., and N. P. Robertson. "Neurotoxicity of novel cancer immunotherapies." Journal of Neurology 266, no. 8 (June 28, 2019): 2087–89. http://dx.doi.org/10.1007/s00415-019-09444-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

McNeel, Douglas G. "Cellular immunotherapies for prostate cancer." Biomedicine & Pharmacotherapy 61, no. 6 (July 2007): 315–22. http://dx.doi.org/10.1016/j.biopha.2006.12.006.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Marmé, Dieter. "Advances in Cancer Therapy: Immunotherapies." Oncology Research and Treatment 39, no. 6 (2016): 324–25. http://dx.doi.org/10.1159/000446635.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Scheetz, Lindsay, Kyung Soo Park, Qiao Li, Pedro R. Lowenstein, Maria G. Castro, Anna Schwendeman, and James J. Moon. "Engineering patient-specific cancer immunotherapies." Nature Biomedical Engineering 3, no. 10 (August 12, 2019): 768–82. http://dx.doi.org/10.1038/s41551-019-0436-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Tanaka, Tomokazu, Jun Nakamura, and Hirokazu Noshiro. "Promising immunotherapies for esophageal cancer." Expert Opinion on Biological Therapy 17, no. 6 (April 11, 2017): 723–33. http://dx.doi.org/10.1080/14712598.2017.1315404.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Lou, Kai-Jye. "Viral boost for cancer immunotherapies." Science-Business eXchange 4, no. 26 (June 2011): 728. http://dx.doi.org/10.1038/scibx.2011.728.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Fujii, Shin-ichiro, Takuya Takayama, Miki Asakura, Kaori Aki, Koji Fujimoto, and Kanako Shimizu. "Dendritic cell-based cancer immunotherapies." Archivum Immunologiae et Therapiae Experimentalis 57, no. 3 (May 29, 2009): 189–98. http://dx.doi.org/10.1007/s00005-009-0025-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Nishi, Tatsuya, and Yosuke Togashi. "Translational Research in Cancer Immunotherapies." Haigan 62, no. 5 (October 20, 2022): 363–70. http://dx.doi.org/10.2482/haigan.62.363.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Milling, Lauren, Yuan Zhang, and Darrell J. Irvine. "Delivering safer immunotherapies for cancer." Advanced Drug Delivery Reviews 114 (May 2017): 79–101. http://dx.doi.org/10.1016/j.addr.2017.05.011.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Lou, Jenny, Li Zhang, and Gang Zheng. "Advancing Cancer Immunotherapies with Nanotechnology." Advanced Therapeutics 2, no. 4 (January 30, 2019): 1800128. http://dx.doi.org/10.1002/adtp.201800128.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Offidani, Massimo, and Maria Teresa Petrucci. "Introduction to “Immunotherapies for Multiple Myeloma”." Pharmaceuticals 13, no. 11 (November 17, 2020): 396. http://dx.doi.org/10.3390/ph13110396.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Kumar, Vijay, Caitlin Bauer, and John H. Stewart Iv. "Chasing Uterine Cancer with NK Cell-Based Immunotherapies." Future Pharmacology 2, no. 4 (December 9, 2022): 642–59. http://dx.doi.org/10.3390/futurepharmacol2040039.

Повний текст джерела

Анотація:

Gynecological cancers, including endometrial adenocarcinoma, significantly contribute to cancer incidence and mortality worldwide. The immune system plays a significant role in endometrial cancer pathogenesis. NK cells, a component of innate immunity, are among the critical innate immune cells in the uterus crucial in menstruation, embryonic development, and fighting infections. NK cell number and function influence endometrial cancer development and progression. Hence, it becomes crucial to understand the role of local (uterine) NK cells in uterine cancer. Uterine NK (uNK) cells behave differently than their peripheral counterparts; for example, uNK cells are more regulated by sex hormones than peripheral NK cells. A deeper understanding of NK cells in uterine cancer may facilitate the development of NK cell-targeted therapies. This review synthesizes current knowledge on the uterine immune microenvironment and NK cell-targeted uterine cancer therapeutics.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Barbari, Cody, Tyler Fontaine, Priyanka Parajuli, Narottam Lamichhane, Silvia Jakubski, Purushottam Lamichhane, and Rahul R. Deshmukh. "Immunotherapies and Combination Strategies for Immuno-Oncology." International Journal of Molecular Sciences 21, no. 14 (July 15, 2020): 5009. http://dx.doi.org/10.3390/ijms21145009.

Повний текст джерела

Анотація:

The advent of novel immunotherapies in the treatment of cancers has dramatically changed the landscape of the oncology field. Recent developments in checkpoint inhibition therapies, tumor-infiltrating lymphocyte therapies, chimeric antigen receptor T cell therapies, and cancer vaccines have shown immense promise for significant advancements in cancer treatments. Immunotherapies act on distinct steps of immune response to augment the body’s natural ability to recognize, target, and destroy cancerous cells. Combination treatments with immunotherapies and other modalities intend to activate immune response, decrease immunosuppression, and target signaling and resistance pathways to offer a more durable, long-lasting treatment compared to traditional therapies and immunotherapies as monotherapies for cancers. This review aims to briefly describe the rationale, mechanisms of action, and clinical efficacy of common immunotherapies and highlight promising combination strategies currently approved or under clinical development. Additionally, we will discuss the benefits and limitations of these immunotherapy approaches as monotherapies as well as in combination with other treatments.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Cunningham, Nicholas, Réjean Lapointe, and Sophie Lerouge. "Biomaterials for enhanced immunotherapy." APL Bioengineering 6, no. 4 (December 1, 2022): 041502. http://dx.doi.org/10.1063/5.0125692.

Повний текст джерела

Анотація:

Cancer immunotherapies have revolutionized the treatment of numerous cancers, with exciting results often superior to conventional treatments, such as surgery and chemotherapy. Despite this success, limitations such as limited treatment persistence and toxic side effects remain to be addressed to further improve treatment efficacy. Biomaterials offer numerous advantages in the concentration, localization and controlled release of drugs, cancer antigens, and immune cells in order to improve the efficacy of these immunotherapies. This review summarizes and highlights the most recent advances in the use of biomaterials for immunotherapies including drug delivery and cancer vaccines, with a particular focus on biomaterials for immune cell delivery.

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Galsky, Matthew D., Arjun V. Balar, Peter C. Black, Matthew T. Campbell, Gail S. Dykstra, Petros Grivas, Shilpa Gupta, et al. "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer." Journal for ImmunoTherapy of Cancer 9, no. 7 (July 2021): e002552. http://dx.doi.org/10.1136/jitc-2021-002552.

Повний текст джерела

Анотація:

A number of immunotherapies have been developed and adopted for the treatment of urothelial cancer (encompassing cancers arising from the bladder, urethra, or renal pelvis). For these immunotherapies to positively impact patient outcomes, optimal selection of agents and treatment scheduling, especially in conjunction with existing treatment paradigms, is paramount. Immunotherapies also warrant specific and unique considerations regarding patient management, emphasizing both the prompt identification and treatment of potential toxicities. In order to address these issues, the Society for Immunotherapy of Cancer (SITC) convened a panel of experts in the field of immunotherapy for urothelial cancer. The expert panel developed this clinical practice guideline (CPG) to inform healthcare professionals on important aspects of immunotherapeutic treatment for urothelial cancer, including diagnostic testing, treatment planning, immune-related adverse events (irAEs), and patient quality of life (QOL) considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with urothelial cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Koury, Jeffrey, Mariana Lucero, Caleb Cato, Lawrence Chang, Joseph Geiger, Denise Henry, Jennifer Hernandez, et al. "Immunotherapies: Exploiting the Immune System for Cancer Treatment." Journal of Immunology Research 2018 (2018): 1–16. http://dx.doi.org/10.1155/2018/9585614.

Повний текст джерела

Анотація:

Cancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and refined enough to safely and effectively combat cancer. Three unique immunotherapies have gained traction in recent decades: adoptive T cell transfer, checkpoint inhibitors, and bivalent antibodies. Each has led to clinically approved therapies, as well as to therapies in preclinical and ongoing clinical trials. In this review, we outline the method by which these 3 immunotherapies function as well as any major immunotherapeutic drugs developed for treating a variety of cancers.

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Zhang, Yangyi, Bethany K. Campbell, Stanley S. Stylli, Niall M. Corcoran, and Christopher M. Hovens. "The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention." Uro 2, no. 2 (April 10, 2022): 74–92. http://dx.doi.org/10.3390/uro2020010.

Повний текст джерела

Анотація:

Advanced prostate cancers have a poor survival rate and a lack of effective treatment options. In order to broaden the available treatments, immunotherapies have been investigated. These include cancer vaccines, immune checkpoint inhibitors, chimeric antigen receptor T cells and bispecific antibodies. In addition, combinations of different immunotherapies and with standard therapy have been explored. Despite the success of the Sipuleucel-T vaccine in the metastatic, castrate-resistant prostate cancer setting, other immunotherapies have not shown the same efficacy in this population at large. Some individual patients, however, have shown remarkable responsiveness to these therapies. Therefore, work is underway to identify which populations will respond positively to therapy via the identification of predictive biomarkers. These include biomarkers of the immunologically active tumour microenvironment and biomarkers indicative of high neoantigen expression in the tumour. This review examines the constitution of the prostate tumour immune microenvironment, explores the effectiveness of immunotherapies, and finally investigates how therapy selection can be optimised by the use of biomarkers.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Mandrup, Ole A., and Kenneth A. Howard. "Bioengineered solutions to improve cancer immunotherapies." Therapeutic Delivery 12, no. 5 (May 2021): 339–41. http://dx.doi.org/10.4155/tde-2021-0019.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Janssen, Eline, Beatriz Subtil, Fàtima de la Jara Ortiz, Henk M. W. Verheul, and Daniele V. F. Tauriello. "Combinatorial Immunotherapies for Metastatic Colorectal Cancer." Cancers 12, no. 7 (July 12, 2020): 1875. http://dx.doi.org/10.3390/cancers12071875.

Повний текст джерела

Анотація:

Colorectal cancer (CRC) is one of the most frequent and deadly forms of cancer. About half of patients are affected by metastasis, with the cancer spreading to e.g., liver, lungs or the peritoneum. The majority of these patients cannot be cured despite steady advances in treatment options. Immunotherapies are currently not widely applicable for this disease, yet show potential in preclinical models and clinical translation. The tumour microenvironment (TME) has emerged as a key factor in CRC metastasis, including by means of immune evasion—forming a major barrier to effective immuno-oncology. Several approaches are in development that aim to overcome the immunosuppressive environment and boost anti-tumour immunity. Among them are vaccination strategies, cellular transplantation therapies, and targeted treatments. Given the complexity of the system, we argue for rational design of combinatorial therapies and consider the implications of precision medicine in this context.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Pruitt, Amy. "Complications of cancer therapies including immunotherapies." Journal of the Neurological Sciences 429 (October 2021): 118016. http://dx.doi.org/10.1016/j.jns.2021.118016.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Barrero, Maria. "Epigenetic Strategies to Boost Cancer Immunotherapies." International Journal of Molecular Sciences 18, no. 6 (May 23, 2017): 1108. http://dx.doi.org/10.3390/ijms18061108.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Walker, Anthony, and Robert Johnson. "Commercialization of cellular immunotherapies for cancer." Biochemical Society Transactions 44, no. 2 (April 11, 2016): 329–32. http://dx.doi.org/10.1042/bst20150240.

Повний текст джерела

Анотація:

Successful commercialization of a cell therapy requires more than proving safety and efficacy to the regulators. The inherent complexity of cellular products delivers particular manufacturing, logistical and reimbursement hurdles that threaten commercial viability for any therapy with a less than spectacular clinical profile that truly changes the standard of care. This is particularly acute for autologous cell therapies where patients receive bespoke treatments manufactured from a sample of their own cells and where economies of scale, which play an important role in containing the production costs for small molecule and antibody therapeutics, are highly limited. Nevertheless, the promise of ‘game-changing’ efficacy, as exemplified by very high levels of complete responses in refractory haematological malignancies, has attracted capital investments on a vast scale, and the attendant pace of technology development provides promising indicators for future clinical and commercial success.

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Villa, Natalie M., Abtin Farahmand, Lin Du, Michael W. Yeh, Stephanie Smooke-Praw, Antoni Ribas, Bartosz Chmielowski, Grace Cherry, and Angela M. Leung. "Endocrinopathies with use of cancer immunotherapies." Clinical Endocrinology 88, no. 2 (October 9, 2017): 327–32. http://dx.doi.org/10.1111/cen.13483.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

HENDERSON, R., S. MOSSMAN, N. NAIRN, and M. CHEEVER. "Cancer vaccines and immunotherapies: emerging perspectives." Vaccine 23, no. 17-18 (March 18, 2005): 2359–62. http://dx.doi.org/10.1016/j.vaccine.2005.01.082.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Zhao, Lei, Jianjun Zhang, Liang Xu, and Hussein A. Abbas. "Novel Cancer Immunotherapies and Antitumor Immunity." Journal of Immunology Research 2019 (July 22, 2019): 1–2. http://dx.doi.org/10.1155/2019/3742061.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Hoare, Joseph, Nicola Campbell, and Elisabete Carapuça. "Oncolytic virus immunotherapies in ovarian cancer." Porto Biomedical Journal 3, no. 1 (August 2018): e7. http://dx.doi.org/10.1016/j.pbj.0000000000000007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Davis, Laurie S. "Flora-ishing guts assist cancer immunotherapies." Science Immunology 3, no. 20 (February 2, 2018): eaat0813. http://dx.doi.org/10.1126/sciimmunol.aat0813.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!